T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation

European Journal of Immunology

Volumn 44, Issue 11, 2014, Pages 3240-3251

  Blachère, Nathalie E ^a,b   Orange, Dana E ^a,c   Santomasso, Bianca D ^a,d   Doerner, Jessica ^a,e   Foo, Patricia K ^a,f   Herre, Margaret ^a   Fak, John ^a   Monette, Sébastien ^d   Gantman, Emily C ^a   Frank, Mayu O ^a   Darnell, Robert B ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Cancer; Cellular immunity; Humoral immunity; Paraneoplastic neurologic disease

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NOVA2 PROTEIN, MOUSE; RITUXIMAB; RNA BINDING PROTEIN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL; AUTOIMMUNITY; B LYMPHOCYTE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CYTOLOGY; GENETICS; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; NERVE CELL; PARANEOPLASTIC NEUROPATHY; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; AUTOIMMUNITY; B-LYMPHOCYTES; BETA-GALACTOSIDASE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CENTRAL NERVOUS SYSTEM; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOLOGIC FACTORS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; RITUXIMAB; RNA-BINDING PROTEINS;

EID: 84916917773     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444624     Document Type: Article

References (35)

1. Darnell, R. B. and Posner, J. B., Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 2003. 349: 1543-1554.
2. Roberts, W. K., Deluca, I. J., Thomas, A., Fak. J., Williams, T., Buckley, N., Dousmanis, A. G. et al., Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J. Clin Invest. 2009. 119: 2042-2051.
3. Graus, F., Dalmou, J., Rene, R., Tora, M., Malats, N., Verschuuren, J. J., Cardenal, F. et al., Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J. Clin. Oncol. 1997. 15: 2866-2872.
4. Darnell, R. B. and Posner, J. B., Observing the invisible: successful tumor immunity in humans. Nat. Immunol. 2003. 4: 201.
5. Darnell, R. B. and DeAngelis, L. M., Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993. 341: 21-22.
6. Tanaka, K., Tanaka, M., Onodera, O., Igarashi, S., Miyatake, T. and Tsuji, S., Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J. Neurol. Sci. 1994. 127: 153-158.
7. Tanaka, M., Tanaka, K., Onodera, O. and Tsuji, S., Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin. Neurol. Neurosurg. 1995. 97: 95-100.
8. Albert, M. L., Darnell, J. C., Bender, A., Francisco, L. M., Bhardwaj, N. and Darnell, R. B., Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 1998. 4: 1321-1324.
9. Albert, M. L., Austin, L. M. and Darnell, R. B., Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 2000. 47: 9-17.
10. Sakai, K., Shirakawa, T., Kitagawa, Y., Li, Y. and Hirose, G., Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization. J. Autoimmun. 2001. 17: 297-302.
11. Tanaka, K., Tanaka, M., Igarashi, S., Onodera, O., Miyatake, T. and Tsuji, S., Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin. Neurol. Neurosurg. 1995. 97: 101-105.
12. DeLuca, I., Blachere, N. E., Santomasso, B. and Darnell, R. B., Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One 2009. 4: e5739.
13. Santomasso, B. D., Roberts, W. K., Thomas, A., Williams, T., Blachere, N. E., Dudley, M. E., Houghton, A. N. et al., A T-cell receptor associated with naturally occurring human tumor immunity. Proc. Natl. Acad. Sci. USA 2007. 104: 19073-19078.
14. Calzascia, T., Loh, J. M., Di Berardino-Besson, W., Masson, F., Guillaume, P., Burkhardt, K., Herrera, P. L. et al., Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes. Glia 2008. 56: 1625-1636.
15. Yang, Y. Y., Yin, G.L. and Darnell, R.B., The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc. Natl. Acad. Sci. USA 1998. 95: 13254-13259.
16. Younger, D. S., Graber, J., Hayakawa-Yano, Y., Parveen, S., Frank, M. and Darnell, R. B., Ri/Nova gene-associated paraneoplastic subacute motor neuronopathy. Muscle Nerve 2013. 47: 617-618.
17. Buckanovich, R. J., Posner, J. B. and Darnell, R. B., Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993. 11: 657-672.
18. Ule, J., Jensen, K. B., Ruggiu, M., Mele, A., Ule, A. and Darnell, R. B., CLIP identifies Nova-regulated RNA networks in the brain. Science 2003. 302: 1212-1215.
19. Zinyk, D. L., Mercer, E. H., Harris, E., Anderson, D. J. and Joyner, A. L., Fate mapping of the mouse midbrain-hindbrain constriction using a site-specific recombination system. Curr. Biol. 1998. 8: 665-668.
20. Tewalt, E. F., Grant, J. M., Granger, E. L., Palmer, D. C., Heuss, N. D., Gregerson, D. S., Restifo, N. P. et al., Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. PLoS Pathog. 2009. 5: e1000457.
21. Overwijk, W. W., Surman, D. R., Tsung, K. and Restifo, N. P., Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods 1997. 12: 117-123.
22. Oukka, M., Cohen-Tannoudji, M., Tanaka, Y., Babinet, C. and Kosmatopoulos, K., Medullary thymic epithelial cells induce tolerance to intracellular proteins. J. Immunol. 1996. 156: 968-975.
23. Zehn, D. and Bevan, M. J., T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006. 25: 261-270.
24. Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F. and Heath, W. R., Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J. Exp. Med. 1997. 186: 239-245.
25. Surman, D. R., Dudley, M. E., Overwijk, W. W. and Restifo, N. P., Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 2000. 164: 562-565.
26. Charo, J., Perez, C., Buschow, C., Jukica, A., Czeh, M. and Blankenstein, T., Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur. J. Immunol. 2011. 41: 3187-3197.
27. Jarry, U., Jeannin, P., Pineau, L., Donnou, S., Delneste, Y. and Couez, D., Efficiently stimulated adult microglia cross-prime naïve CD8+ T cells injected in the brain. Eur. J. Immunol. 2013. 43: 1173-1184.
28. Orange, D., Frank, M., Tian, S., Dousmanis, A., Marmur, R., Buckley, N., Parveen, S. et al., Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch. Neurol. 2012. 69: 1132-1140.
29. Shams'ili, S., de Beukelaar, J., Gratama, J. W., Hooijkaas, H., van den Bent, M., van 't Veer, M. and Sillevis Smitt, P., An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J. Neurol. 2006. 253: 16-20.
30. Dalmau, J., Graus, F., Rosenblum, M. K. and Posner, J. B., Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992. 71: 59-72.
31. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011. 365: 725-733.
32. Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E. et al., Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006. 314: 126-129.
33. Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E. et al., Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 2013. 36: 133-151.
34. Blachere, N. E., Morris, H. K., Braun, D., Saklani, H., Di Santo, J. P., Darnell, R. B. and Albert, M. L., IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation. J. Immunol. 2006. 176: 7288-7300.
35. Gavrieli, Y., Sherman, Y. and Ben-Sasson, S. A., Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992. 119: 493-501.